"immune checkpoint inhibitors" trang 4 - tải miễn phí từ tailieuXANH
Hyperprogression after immunotherapy in patients with malignant tumors of digestive system

Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
9    41    0
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy

Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy
8    54    0
Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer

Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer
11    89    0
Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: The first report

Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: The first report
4    79    0
Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: A case report

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: A case report
7    60    0
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
9    103    0
Prognostic significance of BRAF and NRAS mutations in melanoma: A German study from routine care

Prognostic significance of BRAF and NRAS mutations in melanoma: A German study from routine care
12    116    0
Clinical decision making in the era of immunotherapy for high grade-glioma: Report of four cases

Clinical decision making in the era of immunotherapy for high grade-glioma: Report of four cases
9    53    0
A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer

A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer
8    60    0
Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)
6    65    0
Immunotherapy for non-small cell lung cancers: Biomarkers for predicting responses and strategies to overcome resistance

Immunotherapy for non-small cell lung cancers: Biomarkers for predicting responses and strategies to overcome resistance
10    99    0
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
10    46    0
Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: Study protocol of the TRADE-hypo trial

Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: Study protocol of the TRADE-hypo trial
10    60    0
Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: Conformational changes of the BCloop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab

Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: Conformational changes of the BCloop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab
12    57    0
Response to pembrolizumab in a patient with primary lung adenocarcinoma originated from indium lung

Response to pembrolizumab in a patient with primary lung adenocarcinoma originated from indium lung
5    55    1
Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation

Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation
8    56    1
A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer

A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer
12    45    1
Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-smallcell lung cancer patients: A retrospective multicenter study

Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-smallcell lung cancer patients: A retrospective multicenter study
11    37    1
A composite biomarker of neutrophillymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers

A composite biomarker of neutrophillymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers
11    50    1
Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: A case report

Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: A case report
5    50    1
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.